Edition:
United Kingdom

Quidel Corp (QDEL.OQ)

QDEL.OQ on NASDAQ Stock Exchange Global Select Market

62.74USD
23 May 2018
Change (% chg)

-- (--)
Prev Close
$62.74
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
118,977
52-wk High
$64.71
52-wk Low
$24.21

Chart for

About

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in... (more)

Overall

Beta: 0.92
Market Cap(Mil.): $2,350.02
Shares Outstanding(Mil.): 37.46
Dividend: --
Yield (%): --

Financials

  QDEL.OQ Industry Sector
P/E (TTM): 321.17 35.78 32.90
EPS (TTM): 0.20 -- --
ROI: 2.20 8.07 12.74
ROE: 4.18 11.50 14.64

BRIEF-Quidel Reports Q1 Non-GAAP Earnings Per Share $1.29

* Q1 REVENUE $169.1 MILLION VERSUS I/B/E/S VIEW $150.9 MILLION

08 May 2018

BRIEF-Quidel Corp Says Increased Size Of Board To Eight Members - SEC Filing

* QUIDEL CORP SAYS INCREASED SIZE OF COMPANY'S BOARD OF DIRECTORS TO EIGHT MEMBERS - SEC FILING Source text (https://bit.ly/2q4dLBG) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

04 Apr 2018

BRIEF-Quidel Receives FDA Clearance For Its Instrument

* QUIDEL RECEIVES FDA CLEARANCE FOR ITS POINT-OF-CARE SOFIA® LYME FLUORESCENT IMMUNOASSAY FOR USE WITH SOFIA® 2 INSTRUMENT Source text for Eikon: Further company coverage:

05 Mar 2018

BRIEF-Quidel Q4 Non-Gaap Earnings Per Share $0.56

* QUIDEL REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

21 Feb 2018

BRIEF-Quidel Receives 510(K) Clearance For Quickvue Influenza A+B Test

* QUIDEL RECEIVES 510(K) CLEARANCE FOR QUICKVUE INFLUENZA A+B TEST, ASSAY MEETS FDA'S CLASS II RIDT REQUIREMENTS

13 Feb 2018

BRIEF-Quidel Receives FDA Clearance And Clia Waiver For Its Point-Of-Care Sofia® 2 Instrument

* QUIDEL RECEIVES FDA CLEARANCE AND CLIA WAIVER FOR ITS POINT-OF-CARE SOFIA® 2 INSTRUMENT FOR USE WITH SOFIA STREP A+ ASSAY Source text for Eikon: Further company coverage: ( Bangalore.newsroom@thomsonreuters.com )

22 Dec 2017

BRIEF-Quidel Says Confident In Validity Of Supply Agreement With Beckman Coulter To Sell BNP Assay Assets

* QUIDEL CONFIDENT IN LEGAL STRENGTH AND VALIDITY OF SUPPLY AGREEMENT WITH BECKMAN COULTER TO SELL BNP ASSAY ASSETS

27 Nov 2017

Earnings vs. Estimates